Which has preferable valuation and earnings, SABS or VOR?

SAB Biotherapeutics has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SAB Biotherapeutics $1.32M 184.74 $13.27M -$1.30 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is SABS or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat SAB Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Vor Biopharma N/A N/A N/A

Does the media favor SABS or VOR?

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for SAB Biotherapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat SAB Biotherapeutics' score of 0.61 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SABS or IMTX?

In the previous week, SAB Biotherapeutics and SAB Biotherapeutics both had 4 articles in the media. SAB Biotherapeutics' average media sentiment score of 0.61 beat Immatics' score of 0.25 indicating that SAB Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MGTX or SABS?

In the previous week, MeiraGTx had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 5 mentions for MeiraGTx and 4 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.61 beat MeiraGTx's score of 0.53 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SABS or CVAC?

SAB Biotherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 347.76%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SABS or CGEM more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media favor SABS or CGEM?

In the previous week, Cullinan Therapeutics had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 4 mentions for SAB Biotherapeutics. Cullinan Therapeutics' average media sentiment score of 0.80 beat SAB Biotherapeutics' score of 0.61 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SAB Biotherapeutics (SABS) Competitors

$2.68 -0.15 (-5.30%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$2.63 -0.05 (-1.87%)

As of 04:00 AM Eastern

Compare

SABS vs. VOR, IMTX, MGTX, CVAC, and CGEM

Should you buy SAB Biotherapeutics stock or one of its competitors? SAB Biotherapeutics's main competitors and comparable companies include Vor Biopharma (VOR), Immatics (IMTX), MeiraGTx (MGTX), CureVac (CVAC), and Cullinan Therapeutics (CGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Vor Biopharma?

SAB Biotherapeutics (NASDAQ:SABS) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

SAB Biotherapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for SAB Biotherapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat SAB Biotherapeutics' score of 0.61 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma's return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Vor Biopharma	N/A	N/A	N/A

SAB Biotherapeutics has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	184.74	$13.27M	-$1.30	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

SAB Biotherapeutics presently has a consensus target price of $12.00, indicating a potential upside of 347.76%. Vor Biopharma has a consensus target price of $41.71, indicating a potential upside of 118.86%. Given SAB Biotherapeutics' higher probable upside, equities research analysts plainly believe SAB Biotherapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Vor Biopharma beats SAB Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Immatics?

SAB Biotherapeutics (NASDAQ:SABS) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 347.76%. Immatics has a consensus target price of $19.67, indicating a potential upside of 187.95%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe SAB Biotherapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Immatics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

SAB Biotherapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Immatics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

In the previous week, SAB Biotherapeutics and SAB Biotherapeutics both had 4 articles in the media. SAB Biotherapeutics' average media sentiment score of 0.61 beat Immatics' score of 0.25 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SAB Biotherapeutics has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	184.74	$13.27M	-$1.30	N/A
Immatics	$54.60M	17.10	-$222.26M	-$1.86	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. SAB Biotherapeutics' return on equity of -6.74% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Immatics	-495.71%	-47.41%	-39.45%

Summary

SAB Biotherapeutics beats Immatics on 11 of the 14 factors compared between the two stocks.

How does SAB Biotherapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

MeiraGTx has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SAB Biotherapeutics has lower revenue, but higher earnings than MeiraGTx. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	11.73	-$114.20M	$0.71	14.00
SAB Biotherapeutics	$1.32M	184.74	$13.27M	-$1.30	N/A

In the previous week, MeiraGTx had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 5 mentions for MeiraGTx and 4 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.61 beat MeiraGTx's score of 0.53 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx currently has a consensus target price of $24.71, indicating a potential upside of 148.63%. SAB Biotherapeutics has a consensus target price of $12.00, indicating a potential upside of 347.76%. Given SAB Biotherapeutics' higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

MeiraGTx has a net margin of 19.87% compared to SAB Biotherapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

Summary

MeiraGTx beats SAB Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to CureVac?

SAB Biotherapeutics (NASDAQ:SABS) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

SAB Biotherapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SAB Biotherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 347.76%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, SAB Biotherapeutics had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for SAB Biotherapeutics and 0 mentions for CureVac. SAB Biotherapeutics' average media sentiment score of 0.61 beat CureVac's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
SAB Biotherapeutics	Positive
CureVac	Neutral

CureVac has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	184.74	$13.27M	-$1.30	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of -6.74% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
CureVac	199.92%	-23.03%	-19.09%

Summary

SAB Biotherapeutics beats CureVac on 9 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Cullinan Therapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

SAB Biotherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 347.76%. Cullinan Therapeutics has a consensus price target of $33.71, indicating a potential upside of 139.11%. Given SAB Biotherapeutics' higher probable upside, equities analysts plainly believe SAB Biotherapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

SAB Biotherapeutics' return on equity of -6.74% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

SAB Biotherapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	184.74	$13.27M	-$1.30	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

SAB Biotherapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cullinan Therapeutics had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 4 mentions for SAB Biotherapeutics. Cullinan Therapeutics' average media sentiment score of 0.80 beat SAB Biotherapeutics' score of 0.61 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SAB Biotherapeutics beats Cullinan Therapeutics on 8 of the 14 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$257.49M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.43	199.17	19.37
Price / Sales	184.74	1,157.81	564.77	81.34
Price / Cash	8.28	118.50	77.16	53.04
Price / Book	0.84	16.93	10.70	6.03
Net Income	$13.27M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-6.94%	-4.41%	-2.89%	-2.32%
1 Month Performance	-22.54%	-12.46%	-7.36%	-5.29%
1 Year Performance	16.52%	7.64%	3.00%	-2.94%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	2.264 of 5 stars	$2.68 -5.3%	$12.00 +347.8%	+16.0%	$257.49M	$1.32M	N/A	86	News Coverage
VOR Vor Biopharma	2.4514 of 5 stars	$18.31 -1.5%	$41.71 +127.8%	-41.0%	$1.10B	N/A	N/A	76
IMTX Immatics	3.5145 of 5 stars	$7.50 -3.0%	$20.60 +174.7%	-32.3%	$1.06B	$54.60M	N/A	704	Analyst Forecast
MGTX MeiraGTx	3.0622 of 5 stars	$10.60 -2.9%	$24.71 +133.2%	+26.9%	$1.05B	$81.39M	14.93	393
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. VOR, IMTX, MGTX, CVAC, and CGEM

How does SAB Biotherapeutics compare to Vor Biopharma?

Summary

How does SAB Biotherapeutics compare to Immatics?

Summary

How does SAB Biotherapeutics compare to MeiraGTx?

Summary

How does SAB Biotherapeutics compare to CureVac?

Summary

How does SAB Biotherapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. VOR, IMTX, MGTX, CVAC, and CGEM

How does SAB Biotherapeutics compare to Vor Biopharma?

Which has more volatility and risk, SABS or VOR?

Does the media favor SABS or VOR?

Is SABS or VOR more profitable?

Which has preferable valuation and earnings, SABS or VOR?

Do analysts recommend SABS or VOR?

Do insiders & institutionals believe in SABS or VOR?

Summary

How does SAB Biotherapeutics compare to Immatics?

Do analysts rate SABS or IMTX?

Which has more risk & volatility, SABS or IMTX?

Does the media favor SABS or IMTX?

Do institutionals & insiders believe in SABS or IMTX?

Which has better valuation and earnings, SABS or IMTX?

Is SABS or IMTX more profitable?

Summary

How does SAB Biotherapeutics compare to MeiraGTx?

Which has more risk and volatility, MGTX or SABS?

Do insiders & institutionals believe in MGTX or SABS?

Which has better valuation & earnings, MGTX or SABS?

Does the media refer more to MGTX or SABS?

Do analysts prefer MGTX or SABS?

Is MGTX or SABS more profitable?

Summary

How does SAB Biotherapeutics compare to CureVac?

Which has more risk and volatility, SABS or CVAC?

Do insiders and institutionals hold more shares of SABS or CVAC?

Do analysts recommend SABS or CVAC?

Does the media prefer SABS or CVAC?

Which has preferable valuation and earnings, SABS or CVAC?

Is SABS or CVAC more profitable?

Summary

How does SAB Biotherapeutics compare to Cullinan Therapeutics?

Do analysts recommend SABS or CGEM?

Is SABS or CGEM more profitable?

Which has higher valuation & earnings, SABS or CGEM?

Which has more risk & volatility, SABS or CGEM?

Do institutionals and insiders hold more shares of SABS or CGEM?

Does the media favor SABS or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools